Devil's Claw for Health & Longevity - Quick Reference Sheet

Devil's Claw for Health & Longevity

Created on 09/12/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Dried root of a southern African plant, taken orally as a bitter extract for aching joints and a sore back. Short courses ease flares of long-standing low back pain; hip and knee osteoarthritis results are mixed. Indigestion and diarrhoea are predictable, and no long-term safety data exist. (Full Review)

Protocol

Standard daily dose
50–60 mg harpagoside daily
Aqueous extract standardised to harpagoside, typically 2,400 mg of extract; the regimen carrying the strongest trial support in both low back pain and osteoarthritis
Single versus split dosing
800 mg at each of three meals
All supporting trials used two or three divided doses; no trial has tested once-daily administration
Flare dose
100 mg harpagoside daily, up to 4 weeks
Produced the largest pain-free response in the dose-ranging low-back-pain trial, with no extra adverse events
Time to effect
Time to effect
From 4 weeks
Trial responses appear from four weeks; judging the root after two weeks is judging it too early
Maximal effect
1 to 4 months
Not a fast-acting analgesic; it acts over weeks and does not deliver acute pain relief on demand
Practical cycle pattern
12–16 weeks on, 4 weeks off
A break shorter than four weeks may not distinguish genuine benefit from carryover and natural fluctuation in joint pain

Benefits

Contraindications
  • Active or recent peptic or duodenal ulcer, or upper-gastrointestinal bleeding within 12 months
  • Gallstones or biliary obstruction
  • Pregnancy in any trimester, and breastfeeding
  • Known hypersensitivity to Harpagophytum species or other Pedaliaceae
  • Uncontrolled high blood pressure (≥160/100 mmHg untreated)
  • Symptomatic bradyarrhythmia, atrial fibrillation on rate-control therapy, or heart failure of NYHA Class III–IV
  • Severe liver impairment (Child-Pugh Class C) or eGFR below 30 mL/min/1.73 m²
  • Children and adolescents under 18
  • Antiarrhythmic, chronotropic and inotropic drugs (amiodarone, digoxin, metoprolol)
Key Interactions
  • Vitamin K antagonist anticoagulants (warfarin, acenocoumarol, phenprocoumon)
  • Antiplatelet and other anticoagulant drugs (aspirin, clopidogrel, apixaban)
  • Glucose-lowering drugs (metformin, glipizide, insulin)
  • Non-steroidal anti-inflammatory drugs and corticosteroids (ibuprofen, diclofenac, prednisone)
  • Narrow-therapeutic-index P-glycoprotein substrates (digoxin, dabigatran, ciclosporin, tacrolimus)
  • Over-the-counter acid suppressants and antacids (omeprazole, famotidine, calcium carbonate)
  • Over-the-counter analgesics (aspirin, ibuprofen, naproxen sodium)
  • Supplements with additive bleeding risk (fish oil, garlic, Ginkgo biloba, high-dose vitamin E, nattokinase)
  • Supplements with additive anti-inflammatory or gastric-irritant effects (white willow bark, Boswellia serrata, curcumin, ginger, bromelain)
  • Supplements that lower blood glucose (berberine, chromium, cinnamon extract, alpha-lipoic acid)
  • Other interventions (elective surgery, joint corticosteroid injection, structured physical therapy)

Risk & Side Effects

  • High: Gastrointestinal intolerance
  • Medium: Headache, dizziness and tinnitus
  • Low: Serious upper-gastrointestinal injury and bleeding; hypersensitivity and skin reactions; blood pressure elevation; hyponatremia from inappropriate antidiuretic hormone release
  • Speculative: Cardiac rate and rhythm effects; modulation of drug transport raising exposure to co-administered drugs; kidney injury from blocked excretion; uterine stimulation in pregnancy; sex-dependent blood-chemistry shifts

Monitoring

Marker Target Why
Haemoglobin Men 14.0–15.5 g/dL; women 13.0–14.5 g/dL Detects occult gastrointestinal blood loss
Ferritin 50–100 ng/mL Falls before haemoglobin in slow gastrointestinal bleeding
Serum sodium 138–142 mmol/L Targets the reported inappropriate antidiuretic hormone secretion
Blood pressure <120/75 mmHg Targets the reported raised-pressure case
Alanine aminotransferase Men <25 U/L; women <20 U/L Confirms the liver is unaffected over a course
Estimated glomerular filtration rate >90 mL/min/1.73 m² Kidney clearance, and eligibility given rare reports of herb-related kidney injury
Fasting glucose 75–90 mg/dL Baseline before any additive glucose lowering
High-sensitivity C-reactive protein <1.0 mg/L Tracks the inflammatory process the root is meant to act on
Serum uric acid 3.5–5.5 mg/dL Optional, given the rodent urate-lowering finding
WOMAC or visual analogue pain score No established target; 20% improvement from own baseline Converts a symptom into a comparable number

Cadence: Blood pressure twice weekly for the first four weeks, then monthly; sodium and a full blood count at 4 weeks and 12 weeks; liver enzymes, kidney function, fasting glucose and inflammatory markers at 12 weeks, and thereafter only if a course is repeated.

Qualitative Assessment

  • Morning stiffness duration in minutes, timed on waking
  • Pain-free walking distance, and whether stairs need a handrail
  • Number of rescue analgesic doses taken per week
  • Sleep continuity, specifically waking episodes attributable to joint pain
  • Willingness to load the joint in training, and confidence under load
  • Upper-abdominal comfort after each dose, as the earliest signal to stop